An irregular heartbeat may be a sign of A-fib, which may, in turn, raise dementia risk.
Atrial fibrillation (A-fib) is a condition in which the heart beats irregularly. More specifically, the atria of the heart — the chambers that receive blood and pump it out to the heart’s ventricles and the rest of the body — beat at an irregular rhythm.
A-fib is the most common form of arrhythmia, affecting between 2.7 and 6.1 million adults in the United States.
Previous research has shown that people with A-fib have a higher risk of dementia, and also that people can take blood thinners to reduce this risk.
New research confirms that the above is true, even in people who never experienced a stroke. The new study is the largest of its kind ever conducted.
Boyoung Joung, who is a professor of cardiology and internal medicine at Yonsei University College of Medicine in Seoul, Republic of Korea, is the leading author of the paper, which appears in the European Heart Journal.
A-fib raises dementia, Alzheimer’s risk
In the new research, Prof. Joung and team examined 262,611 adults aged 60 and older who did not have A-fib or dementia at baseline, in 2004.
The scientists accessed the data from the Korea National Health Insurance Service Senior cohort and followed the study participants until 2013.
During the study period, 10,435 participants developed A-fib. Of these, 24.4% also developed dementia. However, only 14.4% of the participants without A-fib developed dementia.
“We found that the people who developed atrial fibrillation had a 50% increased risk of developing dementia compared [with] those who did not develop the condition,” reports Prof. Joung.
“[T]his increased risk remained even after we removed those who suffered a stroke from our calculations. This means that among the general population, an extra 1.4 people per 100 of the population would develop dementia if they were diagnosed with atrial fibrillation. The risk occurred in people aged younger and older than 70 years.”
Prof. Boyoung Joung
“We also found that atrial fibrillation increased the risk of Alzheimer’s disease by 30% and more than doubled the risk of vascular dementia,” continues Prof. Joung.
How blood thinners can help
“However, among people who developed atrial fibrillation and who took oral anticoagulants, such as warfarin, or non-vitamin K anticoagulants, such as dabigatran, rivaroxaban, apixaban, or edoxaban, the risk of subsequently developing dementia reduced by 40% compared [with] patients who did not take anticoagulants.”
On the point of anticoagulants, or blood thinners, Prof. Joung thinks that “non-vitamin K anticoagulants, which have a significantly lower risk of cerebral hemorrhage than warfarin, may be more effective than warfarin in terms of dementia prevention and this will be answered by an ongoing clinical trial.”
The researcher also thinks that more investigations are necessary to determine “whether aggressive rhythm control, such as catheter ablation, helps to prevent dementia.”
“Our study suggests that the strong link between atrial fibrillation and dementia could be weakened if patients took oral anticoagulants. Therefore, doctors should think carefully and be readier to prescribe anticoagulants for atrial fibrillation patients to try to prevent dementia.”
Prof. Gregory Lip, study co-author
Strengths and limitations of the study
The researchers explain that this is the largest study of its kind due to the high number of participants and the long follow-up period.
“With these large figures, we can be sure of our findings,” comments study co-author Gregory Lip, who is a professor of cardiovascular medicine at the University of Liverpool, United Kingdom.
“We also believe that our results can be applied to other populations too, as they confirm similar findings of a link between atrial fibrillation and dementia in studies of people in Western and European countries,” adds Prof. Lip.
The authors caution that the research only shows a link between A-fib and dementia but does not suggest causality.
However, they speculate that a possible mechanism behind the association could be that people with A-fib often have altered blood vessels in the brain, which may have been the result of symptomless ministrokes.
Such brain damage may, over time, lead to dementia, suggest the researchers. Prof. Joung and team go on to point out further limitations to the study.
For instance, they note that they could not identify whether the study participants had paroxysmal or persistent A-fib. Also, A-fib can take place without any noticeable symptoms, so the study may have omitted some cases.
Also, the scientists did not know whether the patients were receiving treatment for A-fib and suggest that successful treatment may have affected dementia risk differently. They also lacked information on the participants’ blood pressure. Finally, the researchers say, there may have been “unidentified confounding factors” that they did not account for.
Prof. Joung concludes, “Dementia is an untreatable disease, and so prevention is important.”
“This study confirms that atrial fibrillation is a risk factor for the development of dementia. Therefore, the prevention of atrial fibrillation may be a means to reduce the incidence of dementia.”
Prof. Boyoung Joung